Bullish
Teen eye disease drug tinlarebant slowed lesion growth 35.7% in trial
Belite Bio (NASDAQ: BLTE) announced it will present previously disclosed Phase 3 DRAGON trial top-line results for tinlarebant at the 27th Fundus Dise...